Nexalin Technology Inc
Exchange: NASDAQSector: HealthcareIndustry: Medical Devices
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman.
Did you know?
Holds 654783.0x more cash than debt — a strong balance sheet.
Current Price
$0.38
+0.03%GoodMoat Value
$0.08
79.4% overvaluedProfile
Valuation (TTM)
Market Cap$7.10M
P/E-0.86
EV—
P/B1.89
Shares Out18.65M
P/Sales23.52
Revenue$301647.00
EV/EBITDA—
Nexalin Technology Inc (NXL) Stock Analysis
Market Cap$7.10M
Current Price$0.38
P/E Ratio-0.86
Forward P/E—
PEG Ratio0.02
EPS$-0.50
Book Value$0.20
P/B Ratio1.89
NXL Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 654,783
Revenue
—
FY20
—
FY21
1M
FY22
—
FY23
—
FY24
—
FY25
Net Income
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
NXL 52-Week Range
$0.35
$1.86
50-Day MA: $0.42200-Day MA: $0.81
Did you know?
Currently near its 52-week low — in the bottom 2% of its range.
Nexalin Technology Inc (NXL) Financial Summary
Nexalin Technology Inc (NXL) is a Healthcare company in the Medical Devices industry, listed on NASDAQ. The stock currently trades at $0.38 with a market capitalization of $7.10M.
Key valuation metrics include a P/E ratio of -0.86, price-to-book ratio of 1.89, and EPS of $-0.50. The company reports a profit margin of -2725.8% and return on equity of -219.4%.
NXL Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $7.10M |
| P/E Ratio | -0.86 |
| EPS | $-0.50 |
| P/B Ratio | 1.89 |
| P/S Ratio | 23.52 |
| Profit Margin | -2725.8% |
| Return on Equity | -219.4% |
NXL Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY20 | $242914.00 | $-3.40M |
| FY21 | $144065.00 | $-6.08M |
| FY22 | $1.32M | $-1.70M |
| FY23 | $110748.00 | $-4.65M |
| FY24 | $168721.00 | $-7.61M |
| FY25 | $301647.00 | $-8.22M |
Nexalin Technology Inc (NXL) Valuation
Based on GoodMoat's DCF model, Nexalin Technology Inc has a fair value estimate of $0.08. At the current price of $0.38, the stock appears 386.2% overvalued relative to our intrinsic value estimate.
NXL Quality Indicators
Nexalin Technology Inc maintains a profit margin of -2725.8% and an operating margin of -2781.7%. Return on equity stands at -219.4%. The current ratio is 4.85.
About Nexalin Technology Inc
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman.
NXL Free Cash Flow
Nexalin Technology Inc generated $-4.96M in trailing twelve-month free cash flow, representing an FCF yield of -69.87%. This low FCF yield may reflect heavy reinvestment or growth spending.
NXL Shares Outstanding
Nexalin Technology Inc has 0.02 billion shares outstanding at a share price of $0.38, giving it a market capitalization of $7.10M.